Sanofi Pasteur has reported that United Nations agency has awarded contracts to Shantha Biotechnics (Shantha) for supplies of pentavalent vaccine SHAN5 (combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus influenza B, and Hepatitis B). The contracts, worth $340m, cover the period 2010-2012.
Sanofi Pasteur, through its existing and new contracts, now provides a full range of vaccines used within the Expanded Program on Immunization (EPI) of the WHO.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “These awarded contracts underline Shantha Biotechnics’ manufacturing facilities. While Shantha Biotechnics is joining the sanofi-aventis Group, those contracts perfectly illustrate our ambition to provide the best vaccines at affordable prices to many people around the world.”